Year: 2024

Planet 13 Announces Q3 2024 Financial Results

Written by Customer Service on November 8, 2024. Posted in Earnings Releases And Operating Results.

Q3 2024 Revenue of $32.2 millionQ3 2024 Net loss of $7.4 millionQ3 2024 Adjusted EBITDA of $1.3 million All figures are reported in United States dollars ($) unless otherwise indicated LAS VEGAS, Nov. 08, 2024 (GLOBE NEWSWIRE) — Planet 13 Holdings Inc. (CSE: PLTH) (OTCQX: PLNH) (“Planet 13” or the “Company”), a leading vertically-integrated multi-state cannabis company, today announced its financial results for the three-month period ended September 30, 2024. Planet 13’s financial statements are prepared in accordance with U.S. Generally Accepted Accounting Principles (“GAAP”). “Despite Florida not moving forward with adult-use, we see a significant growth runway by expanding our store footprint and enhancing cultivation assets in the state. In addition to our Florida operations, we’re focused on driving growth by...

OptimumBank Holdings, Inc. Financial Performance for the Third Quarter of 2024

Written by Customer Service on November 8, 2024. Posted in Public Companies.

Fort Lauderdale, FL, Nov. 08, 2024 (GLOBE NEWSWIRE) — OptimumBank Holdings, Inc. (NASDAQ: OPHC) (“OptimumBank” or the “Company”) today reported robust financial performance for the third quarter of 2024. For the three months ended September 30, 2024, the Company achieved net income of $3.3 million, or $0.34 per basic share and $0.32 per diluted share, compared to net income of $1.2 million, or $0.18 per basic and diluted share, for the same period in 2023. This reflects significant growth in both earnings and profitability year-over-year. Key Financial Highlights: ● Net interest income for the third quarter of 2024 reached $8.962 million, a significant increase of 51.5% from $5.914 million in the third quarter of 2023, primarily driven by a 44.9% rise in average interest-earning assets. ● Net interest margin increased...

Autolus Therapeutics Announces FDA Approval of AUCATZYL® (obecabtagene autoleucel – obe-cel) for adults with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL)

Written by Customer Service on November 8, 2024. Posted in Public Companies.

AUCATZYL is the first CAR T therapy approved by the FDA with no requirement for a REMS program (Risk Evaluation Mitigation Strategy) Approval based on FELIX clinical trial of obe-cel in adult patients with r/r B-ALL Conference call to be held on November 11 at 08:30 am EST/13:30 pm BST: conference call participants should pre-register using the link at the bottom of this press releaseLONDON, Nov. 08, 2024 (GLOBE NEWSWIRE) — Autolus Therapeutics plc (Nasdaq: AUTL), an early-commercial stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces the U.S. Food and Drug Administration (FDA) has granted marketing approval for AUCATZYL® (obecabtagene autoleucel) for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (r/r B-ALL). “Adult...

CNL Strategic Capital Announces Operating Results for Third Quarter 2024

Written by Customer Service on November 8, 2024. Posted in Earnings Releases And Operating Results.

Orlando, Fla., Nov. 08, 2024 (GLOBE NEWSWIRE) — CNL Strategic Capital, LLC (CNL Strategic Capital or the Company) seeks to provide current income and long-term appreciation to investors by acquiring controlling equity stakes in combination with loan positions in privately owned middle-market businesses. The Company announced its operating results for the nine months ended Sept. 30, 2024. Highlights:As of Sept. 30, 2024, CNL Strategic Capital’s portfolio consisted of equity and debt investments in 16 portfolio companies and had approximately $1.2 billion in total assets, compared with approximately $1.0 billion as of Dec. 31, 2023. For the nine months ended Sept. 30, 2024, the Company recognized a net change in unrealized appreciation on investments including unrealized foreign currency gain of approximately $50.7 million and...

Grayscale Investments® Announces Intention to Effect Reverse Share Splits for Grayscale® Bitcoin Mini Trust ETF (Ticker: BTC) and Grayscale® Ethereum Mini Trust ETF (Ticker: ETH)

Written by Customer Service on November 8, 2024. Posted in Dividend Reports And Estimates.

STAMFORD, Conn., Nov. 08, 2024 (GLOBE NEWSWIRE) — Grayscale Investments® (“Grayscale”), an asset management firm with over a decade of expertise in crypto investing, offering more than 25 crypto investment products, today announced its intention to effect reverse share splits of two of its exchange-traded products (“ETPs”), Grayscale® Bitcoin Mini Trust ETF (NYSE Arca: BTC) and Grayscale® Ethereum Mini Trust ETF (NYSE Arca: ETH), with details as follows:ETP Name Old CUSIP New CUSIP Split RatioGrayscale® Bitcoin Mini Trust ETF (NYSE Arca: BTC) 389930 108 389930 207 1:5Grayscale® Ethereum Mini Trust ETF (NYSE Arca: ETH) 38964R 104 38964R 203 1:10Grayscale Bitcoin Mini Trust ETF and Grayscale Ethereum Mini Trust ETF (collectively the “Funds”) are not registered under the Investment Company Act of 1940 (the “1940 Act”)...

FutureFuel Releases Third Quarter 2024 Results

Written by Customer Service on November 8, 2024. Posted in Earnings Releases And Operating Results.

Reports Net Loss of $1.2 Million or $0.03 per Diluted Share, and Adjusted EBITDA of $(1.0) Million CLAYTON, Mo., Nov. 08, 2024 (GLOBE NEWSWIRE) — FutureFuel Corp. (NYSE: FF) (“FutureFuel”), a manufacturer of custom and performance chemicals and biofuels, today announced financial results for the third quarter ended September 30, 2024. Third quarter 2024 Financial Highlights (all comparisons are with the third quarter of 2023)Revenues were $51.1 million, a decrease of 56% or $65.6 million compared to $116.8 million. Net loss was $1.2 million, or $0.03 per diluted share, down from a net income of $2.8 million, or $0.06 per diluted share. Adjusted EBITDA(1) was $(1.0) million, down from $9.7 million.Nine months 2024 Financial Highlights (all comparisons are with the first nine months of 2023)Revenues were $181.8 million, a decrease...

Entera Bio Reports Q3 2024 Financial Results and Provides Business Updates

Written by Customer Service on November 8, 2024. Posted in Earnings Releases And Operating Results.

JERUSALEM, Nov. 08, 2024 (GLOBE NEWSWIRE) — Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of oral peptides and small therapeutic proteins, today reported financial results and key business updates for the quarter ended September 30, 2024. “The third quarter of 2024 drew consistent attention to our pivotal-staged clinical asset, EB613, the first oral PTH(1-34) tablet treatment dedicated to post-menopausal women with high risk osteoporosis. Entera’s proprietary N-Tab™ platform consistently delivered across our oral GLP-2 tablet, oral GLP-1/Glucagon tablet and confidential hypoparathyroidism tablet program. Finally, we are humbled by key additions from around the world to our clinical and scientific advisory board which we view as testament to what we are aspiring to build at Entera,”...

LM Funding America, Inc. Schedules Third Quarter 2024 Financial Results and Business Update Conference Call

Written by Customer Service on November 8, 2024. Posted in Public Companies.

Tampa, FL, Nov. 08, 2024 (GLOBE NEWSWIRE) — LM Funding America, Inc. (NASDAQ: LMFA) (“LM Funding” or the “Company”), a cryptocurrency mining and technology-based specialty finance company, today announced that it will host a conference call on Wednesday, November 13, 2024, at 11:00 a.m. Eastern Time to discuss financial results for the quarter ended September 30, 2024, and provide a business update. The conference call will be available via telephone by dialing toll-free +1 888-506-0062 for U.S. callers or +1 973-528-0011 for international callers and entering access code 424451. A webcast of the call may be accessed at https://www.webcaster4.com/Webcast/Page/2917/51557 or on the investor relations section of the company’s website, https://www.lmfunding.com/investors/news-events/ir-calendar. A webcast replay...

Extendicare Announces New $275 Million Senior Secured Credit Facility

Written by Customer Service on November 8, 2024. Posted in Public Companies.

MARKHAM, Ontario, Nov. 08, 2024 (GLOBE NEWSWIRE) — Extendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE) today announced that it has entered into a new senior secured credit facility for $275.0 million (the “Senior Secured Credit Facility”) with a syndicate of Canadian chartered banks, for a term of three years. The Senior Secured Credit Facility consists of a revolving credit facility for up to $145.0 million (the “Revolving Facility”), which replaces the Company’s former demand credit facilities of $112.3 million, and a delayed draw term loan facility in an amount up to $130.0 million (the “Delayed Draw Facility”). The Revolving Facility is available for working capital and general corporate purposes, including capital expenditures and acquisitions. The Delayed Draw Facility is available until April 30, 2025 to repay the...

Rocky Mountain High Brands Announces Restructuring Of Management And Initiatives

Written by Customer Service on November 8, 2024. Posted in Public Companies.

PLANO, Texas, Nov. 08, 2024 (GLOBE NEWSWIRE) — Rocky Mountain High Brands, Inc. (OTC: RMHB) today announced a management restructuring of the Company, including additional initiatives to optimize the Company’s capabilities and overall business performance. This strategic move marks a new chapter in the Company’s growth and a broader vision for its future. RMHB has retained turn-round specialists well versed in the restructuring of small and large companies both private and public. A new focus will be directed towards cutting expenses, reducing debt and improving customer service along with supplying new operating funds. Through contacts and personal relationships, the consultants are able to jumpstart RMHB and its subsidiaries by maintaining proper finished goods inventory on their own brands and providing shorter lead times...

Year: 2024

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals